The FDA recently announced a recall initiated by Cubist Pharmaceuticals, Inc. that affects four lots of Cubicin (daptomycin for injection). Cubicin is an antibiotic indicated for the treatment of certain types of infections. The recall was prompted by "the presence of [glass particulates] found in a number of vials" from the four lots. No adverse reactions associated with vials containing glass particulates have been reported so far. However, intravenous administration of such particulates could potentially lead to negative health consequences, including life-threatening blockage of the lung arteries. The package insert for Cubicin instructs that the product "should be carefully inspected visually for particulate matter prior to administration."
Source: FDA, http://www.fda.gov/Safety/Recalls/ucm366753.htm